Prior to the Great Recession, healthcare enjoyed a somewhat inflated reputation for its steady-eddy revenue and earnings. Since then, investors have learned that patient visit counts and hospital capital budgets can create quite a bit of volatility – look no further than the muted performance at major device companies like Medtronic (NYSE: MDT), Johnson & Johnson (NYSE: JNJ), or Bard (NYSE: BCR).
And then there's ICU Medical (Nasdaq: ICUI). Flying in the face of conventional rules about how medical device companies are supposed to act, this has often been a volatile performer in terms of its reported results and the long-term stock action reflects that. With financial performance looking a little haggard, but the company's competitive position still fairly strong, this may well be one of those periodic opportunities to pick up shares in an oft-overlooked small-cap med-tech player.
To read more, follow this link:
Time To Board The ICU Medical Roller Coaster
Showing posts with label B Braun. Show all posts
Showing posts with label B Braun. Show all posts
Wednesday, October 19, 2011
Wednesday, August 10, 2011
Investopedia: CareFusion Looking Safe And Sound
There is ample evidence out there that these are not good times for health care companies, so it makes sense for investors to play defense. That makes CareFusion (NYSE:CFN) an interesting opportunity in today's environment. As the company continues to find its way after spinning out from Cardinal Health (NYSE:CAH), CareFusion offers investors a chance to buy into not only a modest topline growth story, but an improving margin story as well - and all at a very reasonable price.
A Decent End to the Fiscal Year
To be sure, CareFusion is not going to excite the growth crowd. Top-line growth for the fourth fiscal quarter was just 3.7%, and only about 2% on a constant currency basis. Growth was helped by better than 7% growth in the critical care business (where infusion grew by double-digits) and offset by an 8% contraction in med tech/services where 14% growth in ChloraPrep was overpowered by divestitures. On a like-for-like basis, this segment would have grown about 5% this quarter.
Continue through the link below:
http://stocks.investopedia.
A Decent End to the Fiscal Year
To be sure, CareFusion is not going to excite the growth crowd. Top-line growth for the fourth fiscal quarter was just 3.7%, and only about 2% on a constant currency basis. Growth was helped by better than 7% growth in the critical care business (where infusion grew by double-digits) and offset by an 8% contraction in med tech/services where 14% growth in ChloraPrep was overpowered by divestitures. On a like-for-like basis, this segment would have grown about 5% this quarter.
Continue through the link below:
http://stocks.investopedia.
Subscribe to:
Posts (Atom)